Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

▪ Objective. SPIRIT 2 is the largest phase 3 prospective randomized open-label trial comparing imatinib (I) 400mg with dasatinib (D) 100mg daily in newly diagnosed chronic phase CML. The primary endpoint was 5 year event-free survival. Methods. 812 (406 in each arm) of 814 patients recruited started...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2018-11, Vol.132 (Supplement 1), p.457-457
Main Authors: O'Brien, Stephen, Cork, Leanne, Bandeira, Valeria, Bescoby, Ruth, Foroni, Letizia, Alaily, Lynn, Osborne, Wendy, Bell-Gorrod, Helen, Latimer, Nicholas, Apperley, Jane, Hedgley, Corinne, Syzdlo, Richard, Byrne, Jennifer, Pocock, Christopher, Ramsahoye, Bernard, Zwingers, Thomas, Wason, James, Copland, Mhairi, Clark, Richard
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:▪ Objective. SPIRIT 2 is the largest phase 3 prospective randomized open-label trial comparing imatinib (I) 400mg with dasatinib (D) 100mg daily in newly diagnosed chronic phase CML. The primary endpoint was 5 year event-free survival. Methods. 812 (406 in each arm) of 814 patients recruited started study medication (median age 53.2, 275/812 (33.8%) were over 60 years old). Patients were recruited at 144 hospitals between August 2008 and March 2013 and randomized to receive either imatinib 400mg or dasatinib 100mg daily. Secondary endpoints included overall survival, rates of treatment failure, cytogenetic/molecular response - RT-PCR BCR-ABL/ABL ratio of
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-110128